Anti-EPHB4 antibodies and methods using same

Patent metadata

Field	Value
Publication number	US-9249222-B2
Application number	US-201213349503-A
Country	US
Kind code	B2
Filing date	Jan 12, 2012
Priority date	Jan 5, 2006
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.

First claim

What is claimed is:

1. A method of inhibiting angiogenesis comprising administration of an effective amount of an anti-EphB4 antibody to a subject in need of such treatment, wherein the anti-EphrinB4 antibody comprises six hypervariable regions (HVRs) and wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:9, 11, 15, 2, 4, and 7.

2. The method of claim 1 , further comprising administering to the subject an effective amount of an anti-angiogenic agent.

3. The method of claim 2 , wherein the anti-angiogenic agent is administered prior to or subsequent to the administration of the anti-EphB4 antibody.

4. The method of claim 2 , wherein the anti-angiogenic agent is administered concurrently with the anti-EphB4 antibody.

5. The method of claim 2 , wherein the anti-angiogenic agent is an anti-VEGF antibody.

6. The method of claim 5 , wherein the anti-VEGF antibody is AVASTIN® (bevacizumab).

7. The method of claim 1 , further comprising administering an effective amount of a chemotherapeutic agent.

8. The method of claim 1 , wherein the antibody comprises a human consensus framework sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, and 41.

9. The method of claim 1 , wherein the antibody comprises human κ subgroup consensus framework sequence selected from the group consisting of SEQ ID NOs:38, 39, 40, and 41.

10. The method of claim 1 , wherein the antibody comprises a variable heavy (VH) subgroup III consensus framework sequence comprising at least a portion or all of:
(a) EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:46);
(b) WVRQAPGKGLEWV (SEQ ID NO:47);
(c) RFTISADTSKNTAYLQMNSLRAEDTAVYYC (SEQ ID NO:48); and
(d) WGQGTLVTVSS (SEQ ID NO:49).

11. The method of claim 1 , wherein the antibody comprises a VH subgroup III consensus framework sequence comprising RFTISRDNSKNTLYLQMNSLRAEDTAVYYC (SEQ ID NO:51).

12. The method of claim 1 , wherein the anti-EphB4 antibody is conjugated to a detectable label or cytotoxic agent.

Assignees

• Wu Yan
• Yan Minhong
• Genentech Inc

Inventors

• Wu Yan
• Yan Minhong

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title